Quick adme quote
Comprehensive Inflammasome Assays
Mechanistic clarity and physiologically relevant models
for streamlined drug discovery
Inflammasome-targeting therapeutics often encounter challenges because the models and assays guiding early decisions lack selectivity, limited translational relevance, and mechanistic depth.
Our advanced assay suite removes uncertainty by combining high-throughput screening with physiologically relevant models and orthogonal readouts, to provide the clarity you need to confidently advance only the strongest candidates.
Mechanistic insight that drives decisions: From screening to validation, confirm on-target activity and mechanism of action.
Physiologically relevant models: THP-1 macrophage cell lines, primary human macrophages, iPSC-derived microglia, and organotypic brain slices deliver translational insight.
Robust, reproducible data: Early confirmation of efficacy and selectivity reduces attrition in later stages.
Partner with real experts: Our scientists guide you through assay selection and optimization to meet your program goals.
Assay Portfolio:
In each assay, inflammasome activation is measured by a combination of optional readouts including; caspase-1 activation, IL-1β and IL-18 secretion (ELISA, multiplex, MSD), ASC speck formation, LDH release to measure pyroptosis and on/off-target toxicity, and flow cytometry and genetic analysis for deeper phenotyping.
THP-1 Cell Line Assay: High-throughput screening to identify lead candidates and concentrations for testing in primary cell assays.
Primary Human Macrophage Assay: Validate efficacy and reproducibility across multiple donors in a translational model. Supports phenotype polarization (M1, M2, TAM-like) for disease relevance.
iPSC-Derived Microglia Assay: Confirm activity in CNS-relevant cell types for neuroinflammation programs. Enables genetic background modeling and disease mutation studies.
Organotypic Brain Slice Assay: Test lead compounds in complex 3D ex vivo models to de-risk transition to in vivo studies.
